


































（Transfusion Related Acute Lung Injury :
TRALI）1）や輸血関連循環過負荷（Transfusion-
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Analysis of transfusion-related adverse events
in Matsuyama Red Cross Hospital over the seven years
Makiko OZAKI*, Noriko NISHIYAMA, Yasushi DOTEUTHI, Jun HASEBE, Satoko TANIMATSU,
Masataka NISHIYAMA, Kanji MATSUI and Eisuke YOKOTA
*Department of Medical Laboratory, Matsuyama Red Cross Hospital
Appropriate monitoring and correct analysis of transfusion-related adverse events are
important to search the causes and prevent the recurrence. Herein, we report the analysis of the
events in8，504 patients who received blood transfusion during the7-year period between2006
and2012at Matsuyama Red Cross Hospital.
The overall incidence of adverse events in homologous blood transfusion including red cell
concentrates ; RCC, fresh frozen plasma ; FFP and platelets ; PC was1．8％ per bag,1．9％ per
patient and 4．6％ per individual patient, respectively. The highest incidence per bag was
encountered in PC（3．2％）, followed by FFP（2．8％）and RCC（1．2％）. Actually, the incidence
in PC transfusion was 11．4％ per individual patient. The incidence in autologous blood
transfusion was significantly lower（0．7％ per bag）as compared to homologous blood（1．8％ per
bag）. The type of adverse events with highest incidence was fever in RCC（0．6％ per bag）and
urticaria in FFP（2．2％）and PC（2．2％）, and also fever in autologous blood（0．6％）. Sever adverse
events occurred in14 patients（32 bags）and mainly caused by allergic reactions. The most
common appearance time of each adverse event was120～150minutes in fever,60～75minutes in
urticaria and any time in respiratory distress and others.
In our experience, the annual incidence of transfusion-related adverse events showed
significant fluctuation, therefore it is needed to evaluate the events over an appropriate long-term
period.
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